Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that... Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.
- Mechanism
- Curator reviewed
ABT-869, a multi-targeted receptor tyrosine kinase inhibitor, has been shown to inhibit of all members of the VEGF and PDGF receptor families (e.g., KDR IC50 value of 4 nM), and have less activity (IC50 values >1 µM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases and serine/threonine kinases. In addition, it exhibits potent anti-proliferative and apoptotic effects on tumor cells dependent on mutant, constitutively active, FLT3 and KIT kinases.
- Primary indication
- Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.Curator reviewed
- Formula / weight
- C21H18FN5O · 375.407 g/mol (avg)
- Also known as
- 1-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-3-(2-FLUORO-5-METHYLPHENYL)UREA · N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea · UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-
- Code names
- A-741439 · ABT-869 · RG-3635
Resolves to
MPVGZUGXCQEXTM-UHFFFAOYSA-NSMILESCC1=CC(NC(=O)NC2=CC=C(C=C2)C2=C3C(N)=NNC3=CC=C2)=C(F)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Linifanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account